Earlier this week PolyPid (NASDAQ:PYPD) reported a major regulatory development for its late-stage surgical site infection-prevention therapy, D-PLEX100. The company announced that it has received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback